[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"patient-blood-management\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:patient-blood-management":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100634771","patient-blood-management-in-obstetrics-100634771",false,"NCT07544017","Patient Blood Management in Obstetrics","The Impact of Implementing a Hospital-wide Patient Blood Management (PBM) Program on Blood Product Utilization and Maternal Outcomes in All Obstetric Deliveries: a Retrospective Observational Study (2018-2025)","PBM","Inclusion Criteria:\n\n* All women delivered at Corniche Hospital during the study period\n\nExclusion Criteria:\n\n* None","FEMALE",{"count":19,"type":20},44000,"ESTIMATED","OBSERVATIONAL","Obstetric anemia and hemorrhage are major causes of maternal morbidity and increased healthcare utilization. Although red blood cell (RBC) transfusion is commonly used, it is associated with higher rates of postpartum complications, including pneumonia, renal failure, and cardiac events (Kloka et al.).\n\nPatient Blood Management (PBM) is an evidence-based approach that aims to optimize a patient's own blood and reduce avoidable transfusion through three pillars: treating anemia and iron deficiency, minimizing blood loss, and avoiding unnecessary transfusion. International guidelines support PBM in obstetrics, but data on comprehensive program implementation remain limited due to barriers such as resource constraints and the need for multidisciplinary coordination.\n\nAims , objectives and Hypotheses Primary Aim To assess the association between PBM implementation and blood product utilisation among all obstetric deliveries at Corniche Hospital between 2018 and 2025.\n\nPrimary Objective To estimate the change over time in the mean number of blood product units transfused per delivery (combined and by product type).\n\nPrimary Hypothesis Increasing PBM maturity over time, particularly following comprehensive PBM implementation in 2022, is associated with a significant reduction in mean blood product units transfused per delivery, after adjusting for changes in case-mix.\n\nSecondary Objectives Secondary objectives include evaluating changes in transfusion-related practice and anemia outcomes, including proportion of deliveries receiving any transfusion; pretransfusion hemoglobin thresholds in non-actively bleeding patients (where definable); predelivery anemia prevalence (and iron therapy utilization where captured).\n\nMaternal outcomes will be evaluated by reporting composite morbidity; postpartum hysterectomy; hospital length of stay; High Dependency unit (HDU)\u002FICU admission and length of stay; 28-day all-cause emergency readmissions; in-hospital mortality. Neonatal outcomes will not be included.\n\nAt Corniche Hospital, prior evaluation in cases of major obstetric hemorrhage showed that PBM reduced blood product use and improved hemoglobin recovery without increasing morbidity (Ansari et al.). This study extends the assessment to all deliveries from 2018-2025 to evaluate hospital-wide changes in transfusion practice and maternal outcomes as PBM implementation matured.",[24,25],"Patient Blood Management","Blood Product Transfusion for All Conditions",[27,28,29],"Blood product transfusion","Obstetrics","Patient blood management","NOT_YET_RECRUITING","2026-04-19",{"date":33,"type":34},"2026-04-22","ACTUAL",{"date":36,"type":20},"2026-04",{"date":38,"type":20},"2026-09",{"name":40,"class":41},"Corniche Hospital","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":42},"100466408","effect-of-the-combined-programme-on-perioperative-anaemiacppa-100466408","NCT05353348","Effect of the Combined Programme on Perioperative Anaemia（CPPA）","Effectiveness of Iron Sucrose Combined With rHuEPO and Ascorbic Acid in Improving Perioperative Anaemia in Patients Undergoing Major Cardiac Surgery","Inclusion Criteria:\n\n* Age 18 years and above\n* Ferritin \\\u003C300µg\u002FL, transferrin saturation \\\u003C25%, male 90\\\u003CHb\\\u003C130g\u002FL or female 90\\\u003CHb\\\u003C120g\u002FL\n* Elective major cardiac surgery (valve replacement, CABG coronary artery bypass surgery or a combination of both)\n* ASA: Grade 1-3\n* Signed informed consent\n\nExclusion Criteria:\n\n1. Allergy or contraindication to iron sucrose or recombinant human erythropoietin or ascorbic acid\n2. Patients with a preoperative temperature \\>37.5 °C or on non-prophylactic antibiotics\n3. Pregnancy or breastfeeding stage\n4. weight ≤ 50 kg\n5. Presence of chronic renal insufficiency, urinary stones, oxalate deposits, gout\n6. Chronic liver disease and\u002For screening alanine transferase\u002Faspartate transferase above normal 3 times or more above the upper limit of the normal range\n7. Family history of haemochromatosis, thalassaemia or transferrin saturation \\> 50%\n8. Known history of iron overload\n9. Other known causes of anaemia (folic acid or vitamin B12 deficiency or haemoglobinopathies, etc.)\n10. Emergency surgery\n11. Use of iron, blood transfusion or related anaemia treatment within 12 weeks prior to surgery\n\nWithdrawal criteria:\n\n1. massive blood transfusion (≥ 10 red blood cells (RBC)\u002F24h)\n2. Preoperative interventions not performed according to standard\n3. Cancellation of surgery","ALL","18 Years",{"count":53,"type":20},110,"INTERVENTIONAL",[56],"NA","We used the preoperative intervention of iron sucrose in combination with human erythropoietin and vitamin C as an innovative combination therapy. This combined treatment strategy aims to improve perioperative anaemia in patients by promoting erythropoiesis and improving iron metabolism. Compared with previous perioperative intravenous iron supplementation, this innovative combination therapy strategy takes into account multiple aspects of iron metabolism as well as the biological mechanisms of erythropoiesis, providing a more comprehensive intervention. Management of perioperative anaemia in previous studies has largely relied on single intravenous iron supplementation therapy, and although this approach has been effective in raising iron levels, its effectiveness may be limited in patients who have impaired iron utilisation or in situations where concurrent stimulation of erythropoiesis is required. The use of iron sucrose in combination with human erythropoietin and vitamin C, on the other hand, is based on an integrative therapeutic concept aimed at providing a more comprehensive response to perioperative anaemia by simultaneously promoting effective iron utilisation and erythropoiesis.",[24,59,60],"Cardiac Surgery","Iron Deficiency Anemia","RECRUITING","2025-01-08",{"date":64,"type":34},"2025-01-10",{"date":66,"type":34},"2023-03-15",{"date":68,"type":20},"2025-04-01",{"name":70,"class":41},"Second Affiliated Hospital, School of Medicine, Zhejiang University"]